Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pan-ELR+ CXC chemokine antibodies

Pan-ELR+ CXC chemokine antibodies

US Patent 10858425 · Granted Dec 8, 2020

Estimated economic value: $694,286,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa2024
PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa2024
Anti-CD11D antibodies and uses thereof2024
CD200R agonist antibodies and uses thereof2022
Anti-PACAP antibody2021
Anti-TrkA antibody2020
Anti-PACAP antibody2019
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2018
Pan-ELR+ CXC chemokine antibodies2018
Anti-CD20− / anti-BAFF bispecific antibodies2018